Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ANTX
#3609
AN2 Therapeutics, Inc. Common Stock
1.1
0
+1.85%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+1.85%
Mudança mensal
-7.56%
Mudança em 6 meses
-3.51%
Mudança anual
+0.92%
Fechamento anterior
1.0
8
Open
1.1
0
Bid
Ask
Low
1.1
0
High
1.1
0
Volume
1
Mercados
Ações
Cuidados de saúde
ANTX
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
19.4 M
29.77 M
30.1 M
—
Valuation ratios
Enterprise value
161.39 M
575.94 M
20.14 M
68.74 M
Price to earnings ratio
-3.48
-7.25
-0.8
-3.67
Price to sales ratio
—
—
—
—
Price to cash flow ratio
4.46
8.8
0.84
3.97
Price to book ratio
1.56
3.76
0.5
0.86
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
0.4
0.47
0.56
0.01
Return on equity %
0.43
0.52
0.63
0.01
Return on invested capital %
2 741.62
1 425.16
1 149
—
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
13.72
7.87
10.07
43.56
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-2.18
-2.26
-1.65
-0.99
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
6.47
4.54
2.8
9.17
Net current asset value per share
6.43
4.68
2.89
9.56
Tangible book value per share
6.22
5.28
2.74
9.46
Working capital per share
5.96
4.09
2.6
8.66
Book value per share
6.22
5.28
2.74
9.46
Notícias
AN2 Therapeutics nomeia Sarah Williams como diretora principal de contabilidade
AN2 Therapeutics appoints Sarah Williams as principal accounting officer
FDA clears IND for epetraborole trial in mycobacterium abscessus
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
An2 Therapeutics (ANTX): diretora financeira vende ações no valor de US$ 8.883
An2 therapeutics (ANTX): cfo Day sells $8883 in shares
CSO da An2 Therapeutics vende ações no valor de US$ 6.507
An2 therapeutics CSO prior sells $6507 in stock
Eizen, AN2 Therapeutics COO, sells $25k in ANTX stock
An2 therapeutics chief development officer sells $9k in stock
AN2 Therapeutics partners with GSK to develop TB treatments